New ALS drug stabilizes decline with a trend toward improved strength and mobility for some

Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline in neurological function that ...
MedPage Today

FDA Panel Supports Tofersen for Rare Genetic ALS

A panel of FDA advisors voted unanimously that plasma neurofilament light chain (NfL), a biomarker of neurodegeneration, is a reasonable surrogate endpoint in amyotrophic lateral sclerosis (ALS) ...
MedPage Today on MSN

Long-Term Tofersen Use May Slow ALS Progression, 3-Year Data Suggest

Early initiation of tofersen (Qalsody) was associated with a numerically slower decline in people with SOD1 amyotrophic ...
Seeking Alpha

FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS

Accelerated approval marks a scientific advancement in treatment of superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) Approval based on reduction of neurofilament, a biomarker ...